8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 11, 2026·SEC
Aclaris Therapeutics, Inc.(ACRS)Earnings, Financials & Key Ratios
ACRS•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryContract Research and Preclinical Services
AboutAclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Show more
- Revenue$8M-58.2%
- EBITDA-$76M+46.2%
- Net Income-$65M+50.8%
- EPS (Diluted)-0.53+69.0%
- Gross Margin73.28%-13.9%
- EBITDA Margin-970.11%-28.7%
- Operating Margin-975.91%-28.7%
- Net Margin-829.58%-17.6%
- ROE-50.2%+40.6%
ACRS Key Insights
Aclaris Therapeutics, Inc. (ACRS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 89 (top 11%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 58.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ACRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACRS Price & Volume
Aclaris Therapeutics, Inc. (ACRS) stock price & volume — 10-year historical chart
Loading chart...
ACRS Growth Metrics
Aclaris Therapeutics, Inc. (ACRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years3.84%
3 Years-35.93%
TTM-52.94%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM46.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.71%
Return on Capital
10 Years-55.4%
5 Years-55.7%
3 Years-58.79%
Last Year-47.65%
ACRS Recent Earnings
Aclaris Therapeutics, Inc. (ACRS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.15+6.3%
$0.16
Rev
$2M+51.0%
$1M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.16-6.7%
$0.15
Rev
$1M-37.5%
$2M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.12+7.7%
$0.13
Rev
$3M+59.3%
$2M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.13+0.0%
$0.13
Rev
$2M+56.2%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.15vs $0.16+6.3% | $2Mvs $1M+51.0% |
| Q1 2026 | Feb 26, 2026 | $0.16vs $0.15-6.7% | $1Mvs $2M-37.5% |
| Q4 2025 | Nov 6, 2025 | $0.12vs $0.13+7.7% | $3Mvs $2M+59.3% |
| Q3 2025 | Aug 7, 2025 | $0.13vs $0.13+0.0% | $2Mvs $1M+56.2% |
Based on last 12 quarters of dataView full earnings history →
ACRS Peer Comparison
Aclaris Therapeutics, Inc. (ACRS) competitors in Contract Research and Preclinical Services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 DERM | 171.19M | 6.22 | -13.23 | 10.2% | -14.82% | -35.57% | 0.00 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 SLDB | 648.99M | 8.33 | -4.19 | -74.45% | 0.12 |
Compare ACRS vs Peers
Aclaris Therapeutics, Inc. (ACRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACRS Income Statement
Aclaris Therapeutics, Inc. (ACRS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.68M | 10.09M | 4.23M | 6.48M | 6.76M | 29.75M | 31.25M | 18.72M | 7.83M | 8.37M |
Revenue Growth % | - | 499.58% | -58.11% | 53.35% | 4.3% | 340.05% | 5.03% | -40.09% | -58.19% | -52.94% |
Cost of Goods Sold | 1.21M | 6.85M | 4.05M | 5.13M | 4.71M | 11.96M | 18.08M | 2.79M | 2.09M | 1.98M |
COGS % of Revenue | 71.72% | 67.88% | 95.93% | 79.19% | 69.71% | 40.2% | 57.86% | 14.91% | 26.72% | - |
Gross Profit | 476K▲ 0% | 3.24M▲ 580.9% | 172K▼ 94.7% | 1.35M▲ 684.3% | 2.05M▲ 51.8% | 17.79M▲ 768.8% | 13.17M▼ 26.0% | 15.93M▲ 21.0% | 5.74M▼ 64.0% | 6.39M▲ 0% |
Gross Margin % | 28.28% | 32.12% | 4.07% | 20.81% | 30.29% | 59.8% | 42.14% | 85.09% | 73.28% | 76.34% |
Gross Profit Growth % | 496.67% | 580.88% | -94.69% | 684.3% | 51.82% | 768.75% | -25.99% | 20.96% | -63.99% | - |
Operating Expenses | 72.9M | 138.66M | 92.73M | 52.26M | 91.77M | 107.65M | 110.53M | 157.86M | 82.11M | 86.87M |
OpEx % of Revenue | 4331.49% | 1374.05% | 2193.66% | 806.25% | 1357.36% | 361.81% | 353.69% | 843.27% | 1049.19% | - |
Selling, General & Admin | 33.11M | 75.65M | 27.83M | 20.53M | 23.62M | 25.13M | 31.1M | 22.2M | 21.97M | 22.58M |
SG&A % of Revenue | 1967.26% | 749.64% | 658.32% | 316.72% | 349.34% | 84.47% | 99.52% | 118.61% | 280.76% | - |
Research & Development | 39.79M | 63.01M | 64.9M | 29.34M | 43.81M | 77.81M | 98.38M | 33.59M | 52.65M | 56.72M |
R&D % of Revenue | 2364.23% | 624.41% | 1535.34% | 452.61% | 648.03% | 261.54% | 314.84% | 179.41% | 672.69% | - |
Other Operating Expenses | 0 | 0 | 0 | 2.39M | 24.34M | 4.7M | -18.96M | 102.07M | 7.49M | 4M |
Operating Income | -72.42M▲ 0% | -135.41M▼ 87.0% | -111.06M▲ 18.0% | -50.91M▲ 54.2% | -89.72M▼ 76.2% | -89.85M▼ 0.1% | -97.36M▼ 8.4% | -141.93M▼ 45.8% | -76.38M▲ 46.2% | -80.48M▲ 0% |
Operating Margin % | -4303.21% | -1341.93% | -2627.35% | -785.44% | -1327.07% | -302.01% | -311.55% | -758.18% | -975.91% | -961.91% |
Operating Income Growth % | -49.12% | -86.98% | 17.99% | 54.16% | -76.23% | -0.15% | -8.35% | -45.79% | 46.19% | - |
EBITDA | -72.02M | -134.09M | -109.47M | -49.59M | -88.8M | -89.06M | -96.49M | -141.13M | -75.92M | -79.95M |
EBITDA Margin % | -4279.32% | -1328.82% | -2589.83% | -765.01% | -1313.42% | -299.33% | -308.79% | -753.87% | -970.11% | -955.6% |
EBITDA Growth % | -48.66% | -86.18% | 18.36% | 54.7% | -79.08% | -0.29% | -8.35% | -46.25% | 46.2% | 43.13% |
D&A (Non-Cash Add-back) | 402K | 1.32M | 1.59M | 1.32M | 923K | 797K | 863K | 807K | 454K | 528K |
EBIT | -53.36M | -84.78M | -91.82M | -48.52M | -65.38M | -85.15M | -116.31M | -52.53M | -64.92M | -73.51M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.95M | 7.64M | 6.98M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.95M | 7.64M | 6.99M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -15.99M | 2.68M | -2.48M | -424K | -1.14M | 2.95M | 8.51M | 9.87M | 11.45M | 10.82M |
Pretax Income | -70.35M▲ 0% | -132.74M▼ 88.7% | -113.54M▲ 14.5% | -51.34M▲ 54.8% | -90.86M▼ 77.0% | -86.91M▲ 4.4% | -88.85M▼ 2.2% | -132.06M▼ 48.6% | -64.92M▲ 50.8% | -69.66M▲ 0% |
Pretax Margin % | -4180.21% | -1315.41% | -2686.11% | -791.98% | -1343.96% | -292.11% | -284.32% | -705.48% | -829.58% | -832.58% |
Income Tax | -1.83M | 2.68M | 0 | -182K | 0 | 0 | -367K | 0 | 0 | 0 |
Effective Tax Rate % | 2.6% | -2.02% | 0% | 0.35% | 0% | 0% | 0.41% | 0% | 0% | 0% |
Net Income | -68.52M▲ 0% | -132.74M▼ 93.7% | -161.35M▼ 21.6% | -51.02M▲ 68.4% | -90.86M▼ 78.1% | -86.91M▲ 4.4% | -88.48M▼ 1.8% | -132.06M▼ 49.3% | -64.92M▲ 50.8% | -69.66M▲ 0% |
Net Margin % | -4071.48% | -1315.41% | -3817.22% | -787.03% | -1343.96% | -292.11% | -283.15% | -705.48% | -829.58% | -832.58% |
Net Income Growth % | -42.52% | -93.71% | -21.56% | 68.38% | -78.11% | 4.35% | -1.81% | -49.26% | 50.84% | 46.5% |
Net Income (Continuing) | -50.46M | -82.1M | -113.54M | -51.15M | -90.86M | -86.91M | -88.48M | -132.06M | -64.92M | -69.66M |
Discontinued Operations | 0 | 0 | 0 | 139K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.44▲ 0% | -4.03▼ 65.2% | -3.46▲ 14.1% | -1.20▲ 65.3% | -1.60▼ 33.3% | -1.33▲ 16.9% | -1.27▲ 4.5% | -1.71▼ 34.6% | -0.53▲ 69.0% | -0.54▲ 0% |
EPS Growth % | -8.44% | -65.16% | 14.14% | 65.32% | -33.33% | 16.88% | 4.51% | -34.65% | 69.01% | 59.71% |
EPS (Basic) | -2.44 | -4.03 | -3.46 | -1.20 | -1.60 | -1.33 | -1.27 | -1.71 | -0.53 | - |
Diluted Shares Outstanding | 28.1M | 32.91M | 41.32M | 42.54M | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M | 128.81M |
Basic Shares Outstanding | 28.1M | 32.91M | 41.32M | 42.54M | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M | 128.81M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ACRS Balance Sheet
Aclaris Therapeutics, Inc. (ACRS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 208.85M | 179.5M | 83.8M | 57.49M | 205.03M | 231.55M | 128.86M | 125.95M | 151.36M | 110.23M |
Cash & Short-Term Investments | 208.85M | 167.97M | 73.27M | 54.13M | 191.41M | 217.57M | 119.11M | 113.59M | 90.75M | 105.42M |
Cash Only | 208.85M | 57.02M | 34.19M | 22.06M | 27.35M | 45.28M | 39.88M | 24.57M | 19.96M | 28.66M |
Short-Term Investments | 0 | 110.95M | 39.08M | 32.07M | 164.06M | 172.29M | 79.23M | 89.02M | 70.79M | 76.76M |
Accounts Receivable | 481K | 563K | 704K | 772K | 623K | 484K | 298K | 318K | 5.57M | 4.81M |
Days Sales Outstanding | 104.32 | 20.36 | 60.79 | 43.47 | 33.63 | 5.94 | 3.48 | 6.2 | 259.55 | 166.35 |
Inventory | -6.36M | 791K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | 42.15 | - | - | - | - | - | - | - | - |
Other Current Assets | 5.88M | 5.37M | 6.72M | 0 | 0 | 13.49M | 9.45M | 12.04M | 55.05M | 0 |
Total Non-Current Assets | 34.66M | 96.07M | 14.49M | 13.29M | 46.18M | 23.05M | 68.55M | 94.38M | 9.1M | 88.49M |
Property, Plant & Equipment | 2.16M | 4.28M | 2.47M | 1.65M | 1.33M | 1.1M | 1.62M | 1.01M | 0 | 2.89M |
Fixed Asset Turnover | 0.78x | 2.36x | 1.71x | 3.92x | 5.06x | 27.07x | 19.29x | 18.57x | - | 4.79x |
Goodwill | 18.5M | 18.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 7.35M | 72.95M | 7.2M | 7.12M | 7.05M | 6.97M | 269K | 0 | 0 | 0 |
Long-Term Investments | 15M | 0 | 0 | 0 | 34.24M | 12.24M | 62.77M | 90.3M | 60.61M | 298.37M |
Other Non-Current Assets | 279K | 332K | 4.83M | 4.51M | 3.55M | 2.73M | 3.89M | 3.07M | -51.52M | 231K |
Total Assets | 243.51M▲ 0% | 275.57M▲ 13.2% | 98.3M▼ 64.3% | 70.78M▼ 28.0% | 251.21M▲ 254.9% | 254.6M▲ 1.3% | 197.41M▼ 22.5% | 220.33M▲ 11.6% | 160.46M▼ 27.2% | 198.72M▲ 0% |
Asset Turnover | 0.01x | 0.04x | 0.04x | 0.09x | 0.03x | 0.12x | 0.16x | 0.08x | 0.05x | 0.05x |
Asset Growth % | 38.29% | 13.16% | -64.33% | -27.99% | 254.9% | 1.35% | -22.46% | 11.61% | -27.17% | -13.19% |
Total Current Liabilities | 12.76M | 27.34M | 22.43M | 14.87M | 22.93M | 21.94M | 30.95M | 31.6M | 28.64M | 27.37M |
Accounts Payable | 7.82M | 11.68M | 9.92M | 5.25M | 9.98M | 10.35M | 8.88M | 4.69M | 13.16M | 14.73M |
Days Payables Outstanding | 2.37K | 622.1 | 892.65 | 373.6 | 773.29 | 315.9 | 179.22 | 613.13 | 2.3K | 2.11K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 551K | 569K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.89M | 0 | 14.18M |
Other Current Liabilities | 0 | 7.44M | 7.48M | 7.08M | 6.59M | 7.5M | 6.11M | 11.59M | 14.94M | 6.06M |
Current Ratio | 16.37x | 6.56x | 3.74x | 3.87x | 8.94x | 10.55x | 4.16x | 3.99x | 5.28x | 4.03x |
Quick Ratio | 16.86x | 6.54x | 3.74x | 3.87x | 8.94x | 10.55x | 4.16x | 3.99x | 5.28x | 4.03x |
Cash Conversion Cycle | - | -559.59 | - | - | - | - | - | - | - | -1.95K |
Total Non-Current Liabilities | 5.49M | 33.1M | 5.95M | 18.26M | 30.94M | 35.04M | 9.27M | 33.18M | 28.73M | 27.7M |
Long-Term Debt | 0 | 29.91M | 0 | 10.65M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.56M | 4.69M |
Deferred Tax Liabilities | 549K | 549K | 549K | 367K | 367K | 367K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4.94M | 2.64M | 5.4M | 7.24M | 30.57M | 34.67M | 9.27M | 13.14M | 11M | 11M |
Total Liabilities | 18.25M | 60.44M | 28.39M | 33.13M | 53.87M | 56.98M | 40.23M | 64.77M | 57.38M | 55.07M |
Total Debt | 142K | 30.52M | 637K | 11.26M | 693K | 684K | 426K | 0 | 2.12M | 1.99M |
Net Debt | -208.71M | -26.5M | -33.55M | -10.81M | -26.66M | -44.59M | -39.45M | -24.57M | -17.84M | -26.68M |
Debt / Equity | 0.00x | 0.14x | 0.01x | 0.30x | 0.00x | 0.00x | 0.00x | - | 0.02x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.33x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 225.26M▲ 0% | 215.12M▼ 4.5% | 69.91M▼ 67.5% | 37.65M▼ 46.1% | 197.34M▲ 424.1% | 197.62M▲ 0.1% | 157.18M▼ 20.5% | 155.55M▼ 1.0% | 103.08M▼ 33.7% | 143.65M▲ 0% |
Equity Growth % | 32.91% | -4.5% | -67.5% | -46.15% | 424.15% | 0.14% | -20.46% | -1.03% | -33.73% | -43.3% |
Book Value per Share | 8.02 | 6.54 | 1.69 | 0.89 | 3.48 | 3.03 | 2.25 | 2.01 | 0.84 | 1.12 |
Total Shareholders' Equity | 225.26M | 215.12M | 69.91M | 37.65M | 197.34M | 197.62M | 157.18M | 155.55M | 103.08M | 143.65M |
Common Stock | 0 | 0 | 0 | 0 | 1K | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -159.44M | -292.17M | -453.53M | -504.54M | -595.41M | -682.32M | -770.8M | -902.86M | -967.78M | -987.61M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -246K | -69K | -66K | -94K | -224K | -897K | -106K | 97K | 610K | 22K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACRS Cash Flow Statement
Aclaris Therapeutics, Inc. (ACRS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -54.66M | -100.81M | -96.44M | -38.63M | -52.13M | -67.57M | -78.33M | -20.07M | -47.11M | -52.2M |
Operating CF Margin % | -3247.95% | -999.02% | -2281.64% | -596% | -771.1% | -227.1% | -250.65% | -107.24% | -602.01% | - |
Operating CF Growth % | -57.97% | -84.42% | 4.33% | 59.94% | -34.95% | -29.6% | -15.92% | 74.37% | -134.68% | -216.7% |
Net Income | -68.52M | -132.74M | -113.54M | -51.02M | -90.86M | -86.91M | -88.48M | -132.06M | -64.92M | -69.66M |
Depreciation & Amortization | 402K | 1.88M | 1.59M | 1.32M | 923K | 797K | 863K | 807K | 454K | 528K |
Stock-Based Compensation | 14.43M | 20.05M | 0 | 11.21M | 14.06M | 15.04M | 20.54M | 10.86M | 12.38M | 9.19M |
Deferred Taxes | -1.84M | 0 | 0 | -182K | 752K | 0 | -367K | 0 | 0 | 0 |
Other Non-Cash Items | 10.67M | 555K | 18.21M | 2.39M | 24.34M | 4.7M | -20.27M | 89.41M | 2.3M | 4.76M |
Working Capital Changes | 865K | 9.44M | -2.7M | -2.36M | -1.34M | -1.2M | 9.39M | 10.92M | 2.67M | 2.98M |
Change in Receivables | 0 | -4.38M | -809K | 4.9M | 149K | 139K | 186K | -20K | 6.14M | 7.48M |
Change in Inventory | 0 | 102K | 605K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 4.56M | 6.96M | -3.16M | -5.22M | 3.65M | 368K | -1.47M | -4.19M | 8.45M | 8.3M |
Cash from Investing | -55.69M | 9.37M | 105.68M | 6.39M | -167.63M | 12.63M | 46.22M | -69.77M | 48.37M | -1.69M |
Capital Expenditures | -1.24M | -1.36M | -1.61M | -453K | -308K | -605K | -1.31M | -121K | -111K | -81K |
CapEx % of Revenue | 73.38% | 13.44% | 38.16% | 6.99% | 4.56% | 2.03% | 4.19% | 0.65% | 1.42% | 0.97% |
Acquisitions | -9.65M | -67.12M | 0 | 0 | 167.32M | -13.23M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -44.81M | 77.84M | 34.19M | 0 | -167.32M | 13.23M | 0 | -35.81M | -833K | 0 |
Cash from Financing | 100.39M | 128.26M | -30.32M | 18.37M | 225.05M | 72.87M | 26.71M | 74.54M | -5.86M | 52.19M |
Debt Issued (Net) | -78K | 29.26M | -30.52M | 10.78M | -11.48M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 100.23M | 100.2M | 207K | 7.74M | 238.2M | 72.74M | 26.71M | 74.91M | 0 | 58.02M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9K |
Other Financing | 235K | -1.21M | 0 | -141K | -1.67M | 123K | -8K | -377K | -5.86M | -5.83M |
Net Change in Cash | -9.97M▲ 0% | 36.82M▲ 469.3% | -21.08M▼ 157.3% | -13.87M▲ 34.2% | 5.29M▲ 138.1% | 17.93M▲ 239.2% | -5.4M▼ 130.1% | -15.31M▼ 183.5% | -4.61M▲ 69.9% | -1.7M▲ 0% |
Free Cash Flow | -55.9M▲ 0% | -102.17M▼ 82.8% | -98.06M▲ 4.0% | -39.09M▲ 60.1% | -52.44M▼ 34.2% | -68.17M▼ 30.0% | -79.63M▼ 16.8% | -20.2M▲ 74.6% | -47.11M▼ 133.3% | -52.27M▲ 0% |
FCF Margin % | -3321.33% | -1012.46% | -2319.8% | -602.99% | -775.65% | -229.13% | -254.84% | -107.88% | -602.01% | -624.75% |
FCF Growth % | -60.47% | -82.77% | 4.02% | 60.14% | -34.17% | -30% | -16.81% | 74.64% | -133.28% | -8.55% |
FCF per Share | -1.99 | -3.10 | -2.37 | -0.92 | -0.92 | -1.05 | -1.14 | -0.26 | -0.38 | -0.41 |
FCF Conversion (FCF/Net Income) | 0.80x | 0.76x | 0.60x | 0.76x | 0.57x | 0.78x | 0.89x | 0.15x | 0.73x | 0.75x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACRS Key Ratios
Aclaris Therapeutics, Inc. (ACRS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -34.72% | -60.28% | -113.22% | -94.86% | -77.33% | -44.01% | -49.88% | -84.46% | -50.2% | -55.89% |
Return on Invested Capital (ROIC) | -69.7% | -99% | -74.04% | -120.83% | -68.13% | -41.64% | -53.94% | -85.6% | -52.98% | -59.52% |
Gross Margin | 28.28% | 32.12% | 4.07% | 20.81% | 30.29% | 59.8% | 42.14% | 85.09% | 73.28% | 76.34% |
Net Margin | -4071.48% | -1315.41% | -3817.22% | -787.03% | -1343.96% | -292.11% | -283.15% | -705.48% | -829.58% | -832.58% |
Debt / Equity | 0.00x | 0.14x | 0.01x | 0.30x | 0.00x | 0.00x | 0.00x | - | 0.02x | 0.01x |
FCF Conversion | 0.80x | 0.76x | 0.60x | 0.76x | 0.57x | 0.78x | 0.89x | 0.15x | 0.73x | 0.75x |
Revenue Growth | - | 499.58% | -58.11% | 53.35% | 4.3% | 340.05% | 5.03% | -40.09% | -58.19% | -52.94% |
Related:ACRS Dividend History·ACRS Revenue History·ACRS Price History·ACRS P/E History·ACRS Financial Ratios·ACRS Institutional Holders
ACRS SEC Filings & Documents
Aclaris Therapeutics, Inc. (ACRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ACRS Frequently Asked Questions
Aclaris Therapeutics, Inc. (ACRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aclaris Therapeutics, Inc. (ACRS) reported $8.4M in revenue for fiscal year 2025.
Aclaris Therapeutics, Inc. (ACRS) saw revenue decline by 58.2% over the past year.
Aclaris Therapeutics, Inc. (ACRS) reported a net loss of $69.7M for fiscal year 2025.
Dividend & Returns
Aclaris Therapeutics, Inc. (ACRS) has a return on equity (ROE) of -50.2%. Negative ROE indicates the company is unprofitable.
Aclaris Therapeutics, Inc. (ACRS) had negative free cash flow of $52.3M in fiscal year 2025, likely due to heavy capital investments.